Advances in the treatment for T2DM: Improving outcomes with empagliflozin/linagliptin combination therapy
15 Jul 2019
Type 2 diabetes mellitus (T2DM) is on the rise owing to the increasing prevalence of obesity and sedentary lifestyles. As such, when considering treatment for patients who are overweight or obese, clinicians should be aware of potential weight gain that is associated with antidiabetic medication.
Related MIMS Drugs